Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 34.3% in February

Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 767,400 shares, an increase of 34.3% from the February 13th total of 571,300 shares. Currently, 1.1% of the company's shares are sold short. Based on an average daily volume of 258,500 shares, the short-interest ratio is presently 3.0 days.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Thursday, March 6th. Finally, StockNews.com downgraded Clearside Biomedical from a "hold" rating to a "sell" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.75.

Clearside Biomedical Stock Performance

NASDAQ:CLSD remained flat at $1.01 during trading hours on Thursday. 132,616 shares of the company's stock traded hands, compared to its average volume of 360,558. The firm has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.05. The stock has a market cap of $76.60 million, a P/E ratio of -2.24 and a beta of 2.10. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $1.80.

Remove Ads

Institutional Trading of Clearside Biomedical

A number of large investors have recently made changes to their positions in CLSD. Johnson & Johnson bought a new position in Clearside Biomedical during the third quarter worth about $105,000. Geode Capital Management LLC raised its position in shares of Clearside Biomedical by 8.8% during the third quarter. Geode Capital Management LLC now owns 731,386 shares of the company's stock worth $929,000 after purchasing an additional 59,089 shares during the period. Investor s Fiduciary Advisor Network LLC bought a new position in shares of Clearside Biomedical during the 4th quarter valued at about $32,000. Finally, Northern Trust Corp grew its position in shares of Clearside Biomedical by 24.0% in the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company's stock valued at $157,000 after purchasing an additional 32,048 shares during the period. Institutional investors own 18.75% of the company's stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.